Molecular therapy for Myocardial Infarction: Cilostazol, a phosphodiesterase inhibitor used in the treatment of peripheral vascular disease,  inhibits DNA damage responses, induces telomerase expression, inhibits telomere shortening, and promotes cardiomyocyte survival after myocardial infarction via up regulation of PNUTS, 3/December/2017, 9.35 pm

Molecular therapy for heart regeneration and repair: A therapeutic mix encompassing Aripiprazole and Cilostazol increases Agrin expression, activates Yap and ERK-mediated signaling,  replaces scar tissue with functional cardiomyocytes, and promotes cardiomyocyte regeneration and repair after myocardial infarction, via up regulation of its target gene, 2/December/2017, 8.39 am
December 2, 2017
Natural product-derived therapy for Stroke: Eucalyptol, isolated from Eucalyptus globulus,  Cinnamomum camphora, Bay leaves, and Rosemary, among others, attenuates hippocampal neurons injury, augments regenerative neurogenesis after Ischemic Stroke, and ameliorates stroke damage and neurological deficits via up regulation of its target genes BDNF and NAMPT, 3/December/2017, 10.03 pm
December 3, 2017
Show all

What they say

A recent study from the Institute for Cardiovascular Regeneration, Centre of Molecular Medicine, Frankfurt, Germany shows that “MicroRNA-34a regulates cardiac ageing and function.” This study was published, in the 7 March  2013 issue of Nature,  by Prof Dimmler, Boon, and others.


What we say

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that:   Molecular therapy for Myocardial Infarction: Cilostazol, a phosphodiesterase inhibitor used in the treatment of peripheral vascular disease,  inhibits DNA damage responses, induces telomerase expression, inhibits telomere shortening, and promotes cardiomyocyte survival after myocardial infarction via up regulation of PNUTS

price-300[easy_payment currency=”USD”]


From Significance of the study to Public Health relevance:

Given that: (1)  cardiovascular disease is the leading cause of death worldwide; (2) the raise of death rate, due to cardiovascular disease, has increased from  123 lakhs in 1990 to 173 lakhs in 2013; (3) 85% of people over 80 years are susceptible to cardiovascular diseases;(4) in India, in 2004, 14.6 lakhs deaths (14% of total deaths) were due to ischemic heart disease; (3) the death due to cardiovascular disease is higher in low-to-middle income countries compared to developed countries; (4) the global economic cost spent in the treatment of cardiovascular disease in 2011 was little more than 10 billion US dollars; (5) an alarming number of people, such as 230 lakhs people, will die from cardiovascular diseases each year by 2030, there is an urgent need to find: (i) a way to induce regeneration of cardiomyocytes that were lost in Myocardial patients; (ii) a cheaper alternative to the existing expensive drugs; and (iv) a side-effect-free Natural product-based drug.


From Research Findings to Therapeutic Opportunity

Cilostazol,  a phosphodiesterase inhibitor, is a vasodilator, which is used to alleviate symptoms of intermittent claudication in patients with peripheral vascular disease.  

This study provides, for the first time, mechanistic insights into how Cilostazol may protect against cardiovascular diseases.  

Cilostazol, by increasing the expression of their target genes, it may increase the expression of PNUTS. (fig.1)Thereby, it may: (1) inhibit DNA damage responses, (2) increase telomerase expression, (3) inhibit telomere shortening; (4) promote cardiomyocyte survival/regeneration; (5) decelerate ageing; and (6) extend life span (fig 1). 

Figure 1. Cilostazol functions as a Cardioprotective agent.  Cilostazol induces the expression of PNUTS and Telomerase to prevent myocardial infarction.  And, thereby, promotes Cardiac regeneration/survival

Figure 2. The chemical structure of Cilostazol. Cilostazol functions as a cardioprotective agent through induction of cardioprotective proteins, including PNUTS.

 

 

Thus, by treating patients with Cilostazol, one may prevent ageing-associated (or, stress-associated) decline in cardiac function. Together, this study suggests that pharmacological formulations encompassing “Cilostazol or its analogs, either alone or  in combination with any of the known compounds,”  may be used to improve cardiac function after myocardial infarction (fig. 2).  

Details of the research findings: 

Idea Proposed/Formulated (with experimental evidence) by:

Dr L Boominathan Ph.D.

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Undisclosed mechanistic information: How Cilostazol increases the expression of PNUTS/Telomerase

Amount: $300#

# Research cooperation

For purchase and payment details, you may reach us at admin@genomediscovery.org


References:

Web:http://genomediscovery.org or http://newbioideas.com/

CitationBoominathan, L.,   Molecular therapy for Myocardial Infarction: Cilostazol, a phosphodiesterase inhibitor used in the treatment of peripheral vascular disease,  inhibits DNA damage responses, induces telomerase expression, inhibits telomere shortening, and promotes cardiomyocyte survival after myocardial infarction via up regulation of PNUTS, 3/December/2017, 9.46 pm,  Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite drop us a line at admin@genomediscovery.org

Comments are closed.